CoChat
Sign Up
Cited by 299

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Exosomes in Angiogenesis and Anti-angiogenic Therapy in Cancers

Olejarz, Wioletta, Kubiak-Tomaszewska, Grażyna, Chrzanowska, Alicja, Lorenc, Tomasz·2020·International Journal of Molecular Sciences
DOI 10.3390/ijms21165840PMC PMC7461570
Open this paper in CoChat — free account

Abstract

Angiogenesis is the process through which new blood vessels are formed from pre-existing ones. Exosomes are involved in angiogenesis in cancer progression by transporting numerous pro-angiogenic biomolecules like vascular endothelial growth factor (VEGF), matrix metalloproteinases (MMPs), and microRNAs. Exosomes promote angiogenesis by suppressing expression of factor-inhibiting hypoxia-inducible factor 1 (HIF-1). Uptake of tumor-derived exosomes (TEX) by normal endothelial cells activates angiogenic signaling pathways in endothelial cells and stimulates new vessel formation. TEX-driven cross-talk of mesenchymal stem cells (MSCs) with immune cells blocks their anti-tumor activity. Effective inhibition of tumor angiogenesis may arrest tumor progression. Bevacizumab, a VEGF-specific antibody, was the first antiangiogenic agent to enter the clinic. The most important clinical problem associated with cancer therapy using VEGF- or VEFGR-targeting agents is drug resistance. Combined strategies based on angiogenesis inhibitors and immunotherapy effectively enhances therapies in various cancers, but effective treatment requires further research.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ijms21165840

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Show all 17 references

Research works printed but not linked: 195

  1. 2019, Contribution of Angiogenesis to Inflammation and Cancer, Front. Oncol., 9, 1399, 10.3389/fonc.2019.01399 · DOI
  2. Jászai, J., and Schmidt, M.H.H. (2019). Trends and Challenges in Tumor Anti-Angiogenic Therapies. Cells, 8. · DOI
  3. Nishida, 2006, Angiogenesis in cancer, Vasc. Health Risk Manag., 2, 213, 10.2147/vhrm.2006.2.3.213 · DOI
  4. Dominiak, A., Chełstowska, B., Olejarz, W., and Nowicka, G. (2020). Communication in the Cancer Microenvironment as a Target for Therapeutic Interventions. Cancers, 12. · DOI
  5. Stec, 2015, Isolation and characterization of circulating micro(nano)vesicles in the plasma of colorectal cancer patients and their interactions with tumor cells, Oncol. Rep., 34, 2768, 10.3892/or.2015.4228 · DOI
  6. Szczepanski, 2019, Exosomes in Cancer: Circulating Immune-Related Biomarkers, BioMed Res. Int., 2019, 1
  7. Aslan, 2019, Tumor-derived exosomes: Implication in angiogenesis and antiangiogenesis cancer therapy, J. Cell. Physiol., 234, 16885, 10.1002/jcp.28374 · DOI
  8. Xie, 2019, The role of exosomal PD-L1 in tumor progression and immunotherapy, Mol. Cancer, 18, 146, 10.1186/s12943-019-1074-3 · DOI
  9. Egeblad, 2020, Communication in tiny packages: Exosomes as means of tumor-stroma communication, Biochim. Biophys. Acta Rev. Cancer, 1873, 188340, 10.1016/j.bbcan.2020.188340 · DOI
  10. Zhao, 2020, Mechanisms of lncRNA/microRNA interactions in angiogenesis, Life Sci., 254, 116900, 10.1016/j.lfs.2019.116900 · DOI
  11. Zeng, 2019, Anti-angiogenesis triggers exosomes release from endothelial cells to promote tumor vasculogenesis, J. Extracell. Vesicles, 8, 1629865, 10.1080/20013078.2019.1629865 · DOI
  12. Javan, 2019, New Insights into Implementation of Mesenchymal Stem Cells in Cancer Therapy: Prospects for Anti-angiogenesis Treatment, Front. Oncol., 9, 840, 10.3389/fonc.2019.00840 · DOI
  13. Zimta, A.A., Baru, O., Badea, M., Buduru, S.D., and Berindan-Neagoe, I. (2019). The Role of Angiogenesis and Pro-Angiogenic Exosomes in Regenerative Dentistry. Int. J. Mol. Sci., 20. · DOI
  14. Olejarz, W., Łacheta, D., and Kubiak-Tomaszewska, G. (2020). Matrix Metalloproteinases as Biomarkers of Atherosclerotic Plaque Instability. Int. J. Mol. Sci., 21. · DOI
  15. Rosenberger, 2019, Stem cell exosomes inhibit angiogenesis and tumor growth of oral squamous cell carcinoma, Sci. Rep., 9, 663, 10.1038/s41598-018-36855-6 · DOI
  16. Sahu, 2011, Microautophagy of cytosolic proteins by late endosomes, Dev. Cell, 20, 131, 10.1016/j.devcel.2010.12.003 · DOI · Paper page
  17. Jadli, 2020, Inside(sight) of tiny communicator: Exosome biogenesis, secretion, and uptake, Mol. Cell. Biochem., 467, 77, 10.1007/s11010-020-03703-z · DOI
  18. Larios, J., Mercier, V., Roux, A., and Gruenberg, J. (2020). ALIX- and ESCRT-III–dependent sorting of tetraspanins to exosomes. J. Cell Biol., 219. · DOI · Paper page
  19. Delevoye, 2019, Lysosome-related organelles as functional adaptations of the endolysosomal system, Curr. Opin. Cell Biol., 59, 147, 10.1016/j.ceb.2019.05.003 · DOI · Paper page
  20. McGough, 2016, Exosomes in developmental signalling, Development, 143, 2482, 10.1242/dev.126516 · DOI
  21. Kanninen, 2016, Exosomes as new diagnostic tools in CNS diseases, Biochim. Biophys. Acta (BBA) Mol. Basis Dis., 1862, 403, 10.1016/j.bbadis.2015.09.020 · DOI
  22. Esa, 2019, Extracellular Vesicles in the Synovial Joint: Is there a Role in the Pathophysiology of Osteoarthritis?, Malays. Orthop. J., 13, 1, 10.5704/MOJ.1903.012 · DOI
  23. Klingeborn, 2017, Roles of exosomes in the normal and diseased eye, Prog. Retin. Eye Res., 59, 158, 10.1016/j.preteyeres.2017.04.004 · DOI
  24. Xavier, C.P.R., Caires, H.R., Barbosa, M.A.G., Bergantim, R., Guimarães, J.E., and Vasconcelos, M.H. (2020). The Role of Extracellular Vesicles in the Hallmarks of Cancer and Drug Resistance. Cells, 9. · DOI
  25. Whiteside, 2016, Exosomes and tumor-mediated immune suppression, J. Clin. Investig., 126, 1216, 10.1172/JCI81136 · DOI
  26. Tkach, 2016, Communication by Extracellular Vesicles: Where We Are and Where We Need to Go, Cell, 164, 1226, 10.1016/j.cell.2016.01.043 · DOI · Paper page
  27. Sarvar, 2016, Mesenchymal Stem Cell-Derived Exosomes: New Opportunity in Cell-Free Therapy, Adv. Pharm. Bull., 6, 293, 10.15171/apb.2016.041 · DOI
  28. Herschlik, 2015, Emerging Roles of Exosomes in Normal and Pathological Conditions: New Insights for Diagnosis and Therapeutic Applications, Front. Immunol., 6, 203
  29. Folkman, 1971, Isolation of a Tumor Factor Responsible for Angiogenesis, J. Exp. Med., 133, 275, 10.1084/jem.133.2.275 · DOI · Paper page
  30. Huang, 2018, Fluid shear stress and tumor metastasis, Am. J. Cancer Res., 8, 763
  31. Weinstein, 2017, A Network Model to Explore the Effect of the Micro-environment on Endothelial Cell Behavior during Angiogenesis, Front. Physiol., 8, 960, 10.3389/fphys.2017.00960 · DOI
  32. Papaccio, 2017, Concise Review: Cancer Cells, Cancer Stem Cells, and Mesenchymal Stem Cells: Influence in Cancer Development, Stem Cells Transl. Med., 6, 2115, 10.1002/sctm.17-0138 · DOI
  33. Zanotelli, 2018, Mechanical Forces in Tumor Angiogenesis, Adv. Exp. Med. Biol., 1092, 91, 10.1007/978-3-319-95294-9_6 · DOI
  34. Fukumura, 2018, Enhancing cancer immunotherapy using antiangiogenics: Opportunities and challenges, Nat. Rev. Clin. Oncol., 15, 325, 10.1038/nrclinonc.2018.29 · DOI · Paper page
  35. Teleanu, R.I., Chircov, C., Stoica, A.E., and Teleanu, D.M. (2019). Tumor Angiogenesis and Anti-Angiogenic Strategies for Cancer Treatment. J. Clin. Med., 9. · DOI
  36. Casanovas, 2018, Unraveling the Role of Angiogenesis in Cancer Ecosystems, Front. Oncol., 8, 248, 10.3389/fonc.2018.00248 · DOI
  37. Vavourakis, V., Wijeratne, P.A., Shipley, R., Loizidou, M., Stylianopoulos, T., and Hawkes, D.J. (2017). A Validated Multiscale In-Silico Model for Mechano-sensitive Tumour Angiogenesis and Growth. PLoS Comput. Biol., 13. · DOI
  38. Varberg, 2018, Kinetic Analysis of Vasculogenesis Quantifies Dynamics of Vasculogenesis and Angiogenesis In Vitro, J. Vis. Exp., 2018, e57044
  39. Kuczynski, 2019, Vessel co-option in cancer, Nat. Rev. Clin. Oncol., 16, 469, 10.1038/s41571-019-0181-9 · DOI
  40. Adams, 2007, Molecular regulation of angiogenesis and lymphangiogenesis, Nat. Rev. Mol. Cell Biol., 8, 464, 10.1038/nrm2183 · DOI
  41. Eichhorn, 2007, Angiogenesis in cancer: Molecular mechanisms, clinical impact, Langenbeck’s Arch. Surg., 392, 371, 10.1007/s00423-007-0150-0 · DOI
  42. Ladomery, 2007, Alternative splicing in angiogenesis: The vascular endothelial growth factor paradigm, Cancer Lett., 249, 133, 10.1016/j.canlet.2006.08.015 · DOI
  43. Ibrahim, 2017, Beyond organoids: In vitro vasculogenesis and angiogenesis using cells from mammals and zebrafish, Reprod. Toxicol., 73, 292, 10.1016/j.reprotox.2017.07.002 · DOI
  44. Duran, 2017, Molecular Regulation of Sprouting Angiogenesis, Compr. Physiol., 8, 153, 10.1002/cphy.c160048 · DOI
  45. Rust, 2018, Pro- and antiangiogenic therapies: Current status and clinical implications, FASEB J., 33, 34, 10.1096/fj.201800640RR · DOI
  46. Phng, 2009, Nrarp Coordinates Endothelial Notch and Wnt Signaling to Control Vessel Density in Angiogenesis, Dev. Cell, 16, 70, 10.1016/j.devcel.2008.12.009 · DOI
  47. Phng, 2013, Filopodia are dispensable for endothelial tip cell guidance, J. Cell Sci., 140, 4031
  48. Chen, 2019, The endothelial tip-stalk cell selection and shuffling during angiogenesis, J. Cell Commun. Signal., 13, 291, 10.1007/s12079-019-00511-z · DOI
  49. Groppa, 2018, EphrinB2/EphB4 signaling regulates non-sprouting angiogenesis by VEGF, EMBO Rep., 19, e45054, 10.15252/embr.201745054 · DOI
  50. Brindle, 2006, Signaling and Functions of Angiopoietin-1 in Vascular Protection, Circ. Res., 98, 1014, 10.1161/01.RES.0000218275.54089.12 · DOI
  51. Batlle, 2019, Regulation of tumor angiogenesis and mesenchymal-endothelial transition by p38alpha through TGF-beta and JNK signaling, Nat. Commun., 10, 3071, 10.1038/s41467-019-10946-y · DOI · Paper page
  52. Ribatti, 2005, Microvascular density, vascular endothelial growth factor immunoreactivity in tumor cells, vessel diameter and intussusceptive microvascular growth in primary melanoma, Oncol. Rep., 14, 81
  53. Mentzer, 2014, Intussusceptive angiogenesis: Expansion and remodeling of microvascular networks, Angiogenesis, 17, 499, 10.1007/s10456-014-9428-3 · DOI
  54. Bussolati, 2011, Tumor exploits alternative strategies to achieve vascularization, FASEB J., 25, 2874, 10.1096/fj.10-180323 · DOI
  55. Chopra, 2018, Insights into Endothelial Progenitor Cells: Origin, Classification, Potentials, and Prospects, Stem Cells Int., 2018, 1, 10.1155/2018/9847015 · DOI
  56. Nakamura, 2009, Adiponectin promotes migration activities of endothelial progenitor cells via Cdc42/Rac1, FEBS Lett., 583, 2457, 10.1016/j.febslet.2009.07.011 · DOI
  57. Kopp, 2006, Contribution of endothelial progenitors and proangiogenic hematopoietic cells to vascularization of tumor and ischemic tissue, Curr. Opin. Hematol., 13, 175, 10.1097/01.moh.0000219664.26528.da · DOI
  58. Chang, 2007, Hypoxia, Hormones, and Endothelial Progenitor Cells in Hemangioma, Lymphat. Res. Biol., 5, 237, 10.1089/lrb.2007.1014 · DOI
  59. Zhang, 2019, Molecular Mechanisms and Anticancer Therapeutic Strategies in Vasculogenic Mimicry, J. Cancer, 10, 6327, 10.7150/jca.34171 · DOI
  60. Angara, 2017, Vascular Mimicry: A Novel Neovascularization Mechanism Driving Anti-Angiogenic Therapy (AAT) Resistance in Glioblastoma, Transl. Oncol., 10, 650, 10.1016/j.tranon.2017.04.007 · DOI
  61. Baeten, 2009, Prognostic Role of Vasculogenic Mimicry in Colorectal Cancer, Dis. Colon Rectum, 52, 2028, 10.1007/DCR.0b013e3181beb4ff · DOI
  62. Li, 2009, Vasculogenic Mimicry: A New Prognostic Sign of Gastric Adenocarcinoma, Pathol. Oncol. Res., 16, 259, 10.1007/s12253-009-9220-7 · DOI
  63. Wang, 2010, Glioblastoma stem-like cells give rise to tumour endothelium, Nature, 468, 829, 10.1038/nature09624 · DOI
  64. Mei, 2017, Glioblastoma stem cell differentiation into endothelial cells evidenced through live-cell imaging, Neuro Oncol., 19, 1109, 10.1093/neuonc/nox016 · DOI
  65. Vitiani, 2010, Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells, Nature, 468, 824, 10.1038/nature09557 · DOI
  66. Lugano, 2019, Tumor angiogenesis: Causes, consequences, challenges and opportunities, Cell. Mol. Life Sci., 77, 1745, 10.1007/s00018-019-03351-7 · DOI
  67. Welsh, 2013, VEGFA and tumour angiogenesis, J. Intern. Med., 273, 114, 10.1111/joim.12019 · DOI
  68. Apte, 2019, VEGF in Signaling and Disease: Beyond Discovery and Development, Cell, 176, 1248, 10.1016/j.cell.2019.01.021 · DOI · Paper page
  69. Li, 2019, HIF-1alpha/VEGF signaling-mediated epithelial-mesenchymal transition and angiogenesis is critically involved in anti-metastasis effect of luteolin in melanoma cells, Phytother. Res., 33, 798, 10.1002/ptr.6273 · DOI
  70. Fantozzi, 2014, VEGF-Mediated Angiogenesis Links EMT-Induced Cancer Stemness to Tumor Initiation, Cancer Res., 74, 1566, 10.1158/0008-5472.CAN-13-1641 · DOI
  71. Pepper, 2001, Role of the Matrix Metalloproteinase and Plasminogen Activator–Plasmin Systems in Angiogenesis, Arter. Thromb. Vasc. Biol., 21, 1104, 10.1161/hq0701.093685 · DOI
  72. Koolwijk, 2008, Endothelial sprouting and angiogenesis: Matrix metalloproteinases in the lead, Cardiovasc. Res., 78, 203, 10.1093/cvr/cvm102 · DOI
  73. Autiero, 2003, Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1, Nat. Med., 9, 936, 10.1038/nm884 · DOI
  74. Schomber, 2007, Placental growth factor-1 attenuates vascular endothelial growth factor-A-dependent tumor angiogenesis during beta cell carcinogenesis, Cancer Res., 67, 10840, 10.1158/0008-5472.CAN-07-1034 · DOI
  75. Didiasova, 2014, From Plasminogen to Plasmin: Role of Plasminogen Receptors in Human Cancer, Int. J. Mol. Sci., 15, 21229, 10.3390/ijms151121229 · DOI
  76. Calvo, 2016, Antithrombin controls tumor migration, invasion and angiogenesis by inhibition of enteropeptidase, Sci. Rep., 6, 27544, 10.1038/srep27544 · DOI
  77. Thijssen, 2018, Targeting PDGF-mediated recruitment of pericytes blocks vascular mimicry and tumor growth, J. Pathol., 246, 447, 10.1002/path.5152 · DOI
  78. Betsholtz, 2004, Insight into the physiological functions of PDGF through genetic studies in mice, Cytokine Growth Factor Rev., 15, 215, 10.1016/j.cytogfr.2004.03.005 · DOI · Paper page
  79. Guo, 2003, Platelet-Derived Growth Factor-B Enhances Glioma Angiogenesis by Stimulating Vascular Endothelial Growth Factor Expression in Tumor Endothelia and by Promoting Pericyte Recruitment, Am. J. Pathol., 162, 1083, 10.1016/S0002-9440(10)63905-3 · DOI
  80. Ornitz, 2015, The Fibroblast Growth Factor signaling pathway, Wiley Interdiscip. Rev. Dev. Biol., 4, 215, 10.1002/wdev.176 · DOI · Paper page
  81. Presta, 2005, Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis, Cytokine Growth Factor Rev., 16, 159, 10.1016/j.cytogfr.2005.01.004 · DOI
  82. Turner, 2010, Fibroblast growth factor signalling: From development to cancer, Nat. Rev. Cancer, 10, 116, 10.1038/nrc2780 · DOI
  83. Yu, 2017, FGF-dependent metabolic control of vascular development, Nature, 545, 224, 10.1038/nature22322 · DOI
  84. Akwii, R.G., Sajib, S., Zahra, F.T., and Mikelis, C.M. (2019). Role of Angiopoietin-2 in Vascular Physiology and Pathophysiology. Cells, 8. · DOI
  85. Jayson, 2016, Antiangiogenic therapy in oncology: Current status and future directions, Lancet, 388, 518, 10.1016/S0140-6736(15)01088-0 · DOI
  86. Papapetropoulos, 2000, Angiopoietin-1 Inhibits Endothelial Cell Apoptosis via the Akt/Survivin Pathway, J. Biol. Chem., 275, 9102, 10.1074/jbc.275.13.9102 · DOI
  87. Shim, 2007, Angiopoietin: A TIE(d) Balance in Tumor Angiogenesis, Mol. Cancer Res., 5, 655, 10.1158/1541-7786.MCR-07-0072 · DOI
  88. Buehler, 2013, Expression of angiopoietin-TIE system components in angiosarcoma, Mod. Pathol., 26, 1032, 10.1038/modpathol.2013.43 · DOI
  89. Todorova, 2017, Extracellular Vesicles in Angiogenesis, Circ. Res., 120, 1658, 10.1161/CIRCRESAHA.117.309681 · DOI
  90. Lv, 2016, The role of hypoxia-inducible factors in tumor angiogenesis and cell metabolism, Gene Funct. Dis., 4, 19, 10.1016/j.gendis.2016.11.003 · DOI
  91. Gannon, 2002, Overexpression of vascular endothelial growth factor-A165 enhances tumor angiogenesis but not metastasis during beta-cell carcinogenesis, Cancer Res., 62, 603
  92. Lane, 2011, Everolimus and PTK/ZK show synergistic growth inhibition in the orthotopic BL16/BL6 murine melanoma model, Cancer Chemother. Pharmacol., 67, 193, 10.1007/s00280-010-1307-z · DOI
  93. Ludwig, 2018, Potential roles of tumor-derived exosomes in angiogenesis, Expert Opin. Ther. Targ., 22, 409, 10.1080/14728222.2018.1464141 · DOI
  94. Kucharzewska, 2013, Exosomes reflect the hypoxic status of glioma cells and mediate hypoxia-dependent activation of vascular cells during tumor development, Proc. Natl. Acad. Sci. USA, 110, 7312, 10.1073/pnas.1220998110 · DOI · Paper page
  95. Kaur, 2009, Vasculostatin inhibits intracranial glioma growth and negatively regulates in vivo angiogenesis through a CD36-dependent mechanism, Cancer Res., 69, 1212, 10.1158/0008-5472.CAN-08-1166 · DOI
  96. Taverna, 2011, Role of exosomes released by chronic myelogenous leukemia cells in angiogenesis, Int. J. Cancer, 130, 2033, 10.1002/ijc.26217 · DOI
  97. Whiteside, 2016, Tumor-Derived Exosomes and Their Role in Cancer Progression, Adv. Clin. Chem., 74, 103, 10.1016/bs.acc.2015.12.005 · DOI
  98. Huang, 2015, Exosomal Transfer of Vasorin Expressed in Hepatocellular Carcinoma Cells Promotes Migration of Human Umbilical Vein Endothelial Cells, Int. J. Biol. Sci., 11, 961, 10.7150/ijbs.11943 · DOI
  99. Stenovec, 2018, PKH26 labeling of extracellular vesicles: Characterization and cellular internalization of contaminating PKH26 nanoparticles, Biochim. Biophys. Acta (BBA) Biomembr., 1860, 1350, 10.1016/j.bbamem.2018.03.013 · DOI
  100. Sherwood, 1971, Tumor Angiogenesis: Therapeutic Implications, N. Engl. J. Med., 285, 1182, 10.1056/NEJM197111182852108 · DOI · Paper page
  101. Summers, 2010, FDA Drug Approval Summary: Bevacizumab plus Interferon for Advanced Renal Cell Carcinoma, Oncologist, 15, 104, 10.1634/theoncologist.2009-0250 · DOI
  102. Elkenawi, 2013, Angiogenesis inhibitors in cancer therapy: Mechanistic perspective on classification and treatment rationales, Br. J. Pharmacol., 170, 712, 10.1111/bph.12344 · DOI
  103. Vasudev, 2014, Anti-angiogenic therapy for cancer: Current progress, unresolved questions and future directions, Angiogenesis, 17, 471, 10.1007/s10456-014-9420-y · DOI
  104. Katoh, 2013, Therapeutics targeting angiogenesis: Genetics and epigenetics, extracellular miRNAs and signaling networks (Review), Int. J. Mol. Med., 32, 763, 10.3892/ijmm.2013.1444 · DOI
  105. Haibe, 2020, Resistance Mechanisms to Anti-angiogenic Therapies in Cancer, Front. Oncol., 10, 221, 10.3389/fonc.2020.00221 · DOI
  106. Olejarz, 2020, Tumor-Derived Exosomes in Immunosuppression and Immunotherapy, J. Immunol. Res., 2020, 1, 10.1155/2020/6272498 · DOI
  107. Melegh, Z., and Oltean, S. (2019). Targeting Angiogenesis in Prostate Cancer. Int. J. Mol. Sci., 20. · DOI
  108. McKay, 2016, A Randomized Phase II Trial of Short-Course Androgen Deprivation Therapy with or without Bevacizumab for Patients with Recurrent Prostate Cancer after Definitive Local Therapy, J. Clin. Oncol., 34, 1913, 10.1200/JCO.2015.65.3154 · DOI
  109. Kelly, 2012, Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone with or without Bevacizumab in Men with Metastatic Castration-Resistant Prostate Cancer: CALGB 90401, J. Clin. Oncol., 30, 1534, 10.1200/JCO.2011.39.4767 · DOI
  110. Lu, 2019, Novel human Ab against vascular endothelial growth factor receptor 2 shows therapeutic potential for leukemia and prostate cancer, Cancer Sci., 110, 3773, 10.1111/cas.14208 · DOI
  111. Moawad, 2020, Angiogenesis in Hepatocellular Carcinoma; Pathophysiology, Targeted Therapy, and Role of Imaging, J. Hepatocell. Carcinoma, 7, 77, 10.2147/JHC.S224471 · DOI
  112. Llovet, 2016, Hepatocellular carcinoma, Nat. Rev. Dis. Prim., 2, 16018, 10.1038/nrdp.2016.18 · DOI · Paper page
  113. Bruix, 2017, Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): A randomised, double-blind, placebo-controlled, phase 3 trial, Lancet, 389, 56, 10.1016/S0140-6736(16)32453-9 · DOI
  114. Meyer, 2018, Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma, N. Engl. J. Med., 379, 54, 10.1056/NEJMoa1717002 · DOI
  115. Kuczynski, 2019, Vessel co-option and resistance to anti-angiogenic therapy, Angiogenesis, 1, 55
  116. Longo, V., Brunetti, O., Azzariti, A., Galetta, D., Nardulli, P., Leonetti, F., and Silvestris, N. (2019). Strategies to Improve Cancer Immune Checkpoint Inhibitors Efficacy, Other than Abscopal Effect: A Systematic Review. Cancers, 11. · DOI
  117. Kim, 2019, Major clinical research advances in gynecologic cancer in 2018, J. Gynecol. Oncol., 30, 18, 10.3802/jgo.2019.30.e18 · DOI
  118. Modest, 2019, Treatment sequencing in metastatic colorectal cancer, Eur. J. Cancer, 109, 70, 10.1016/j.ejca.2018.12.019 · DOI
  119. Lopez, 2019, Targeting Angiogenesis in Colorectal Carcinoma, Drugs, 79, 63, 10.1007/s40265-018-1037-9 · DOI
  120. Aalders, 2017, Anti-angiogenic treatment in breast cancer: Facts, successes, failures and future perspectives, Cancer Treat. Rev., 53, 98, 10.1016/j.ctrv.2016.12.009 · DOI
  121. Shukla, 2020, The Story of Angiogenesis Inhibitors in Non–small-cell Lung Cancer: The Past, Present, and Future, Clin. Lung Cancer, 21, 308, 10.1016/j.cllc.2020.02.024 · DOI
  122. Li, 2018, Angiogenesis in pancreatic cancer: Current research status and clinical implications, Angiogenesis, 22, 15, 10.1007/s10456-018-9645-2 · DOI
  123. Annese, T., Tamma, R., Ruggieri, S., and Ribatti, D. (2019). Angiogenesis in Pancreatic Cancer: Pre-Clinical and Clinical Studies. Cancers, 11. · DOI
  124. Schulte, 2020, Anti-angiogenic therapies in the management of glioblastoma, Chin. Clin. Oncol., 9, 3
  125. Zhang, 2019, Glioblastoma Treatment Modalities besides Surgery, J. Cancer, 10, 4793, 10.7150/jca.32475 · DOI
  126. Tannock, 2013, Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): A phase 3, double-blind randomised trial, Lancet Oncol., 14, 760, 10.1016/S1470-2045(13)70184-0 · DOI
  127. Michaelson, 2014, Randomized, Placebo-Controlled, Phase III Trial of Sunitinib Plus Prednisone Versus Prednisone Alone in Progressive, Metastatic, Castration-Resistant Prostate Cancer, J. Clin. Oncol., 32, 76, 10.1200/JCO.2012.48.5268 · DOI
  128. Petrylak, 2015, Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): A randomised, double-blind, placebo-controlled phase 3 trial, Lancet Oncol., 16, 417, 10.1016/S1470-2045(15)70025-2 · DOI
  129. Kudo, 2018, Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial, Lancet, 391, 1163, 10.1016/S0140-6736(18)30207-1 · DOI · Paper page
  130. Zhu, 2019, Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): A randomised, double-blind, placebo-controlled, phase 3 trial, Lancet Oncol., 20, 282, 10.1016/S1470-2045(18)30937-9 · DOI
  131. Flaherty, 2013, Phase III Trial of Carboplatin and Paclitaxel with or without Sorafenib in Metastatic Melanoma, J. Clin. Oncol., 31, 373, 10.1200/JCO.2012.42.1529 · DOI
  132. Coleman, 2017, Bevacizumab and paclitaxel–carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): A multicentre, open-label, randomised, phase 3 trial, Lancet Oncol., 18, 779, 10.1016/S1470-2045(17)30279-6 · DOI
  133. Tabernero, 2012, Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients with Metastatic Colorectal Cancer Previously Treated with an Oxaliplatin-Based Regimen, J. Clin. Oncol., 30, 3499, 10.1200/JCO.2012.42.8201 · DOI · Paper page
  134. Miller, 2007, Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer, N. Engl. J. Med., 357, 2666, 10.1056/NEJMoa072113 · DOI
  135. Vervenne, 2009, Phase III Trial of Bevacizumab in Combination With Gemcitabine and Erlotinib in Patients with Metastatic Pancreatic Cancer, J. Clin. Oncol., 27, 2231, 10.1200/JCO.2008.20.0238 · DOI
  136. Wick, 2017, Lomustine and Bevacizumab in Progressive Glioblastoma, N. Engl. J. Med., 377, 1954, 10.1056/NEJMoa1707358 · DOI
  137. Hida, K., Maishi, N., Annan, D.A.-M., and Hida, Y. (2018). Contribution of Tumor Endothelial Cells in Cancer Progression. Int. J. Mol. Sci., 19. · DOI
  138. Bae, 2018, Exosomes derived from cancerous and non-cancerous cells regulate the anti-tumor response in the tumor microenvironment, Genes Cancer, 9, 87, 10.18632/genesandcancer.172 · DOI
  139. Skog, 2008, Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers, Johan. Nat. Cell. Biol., 10, 1470, 10.1038/ncb1800 · DOI · Paper page
  140. Hong, B.S., Cho, J.-H., Kim, H., Choi, E.-J., Rho, S., Kim, J., Kim, J.H., Choi, D.-S., Kim, Y.-K., and Hwang, D. (2009). Colorectal cancer cell-derived microvesicles are enriched in cell cycle-related mRNAs that promote proliferation of endothelial cells. BMC Genom., 10. · DOI
  141. Ludwig, 2018, Exosomes from HNSCC Promote Angiogenesis through Reprogramming of Endothelial Cells, Mol. Cancer Res., 16, 1798, 10.1158/1541-7786.MCR-18-0358 · DOI
  142. Whiteside, 2018, Exosome and mesenchymal stem cell cross-talk in the tumor microenvironment, Semin. Immunol., 35, 69, 10.1016/j.smim.2017.12.003 · DOI
  143. Bergenfelz, 2014, WNT5A induces release of exosomes containing pro-angiogenic and immunosuppressive factors from malignant melanoma cells, Mol. Cancer, 13, 88, 10.1186/1476-4598-13-88 · DOI · Paper page
  144. Millimaggi, 2007, Tumor Vesicle—Associated CD147 Modulates the Angiogenic Capability of Endothelial Cells, Neoplasia, 9, 349, 10.1593/neo.07133 · DOI
  145. Lang, 2017, Glioma cells promote angiogenesis through the release of exosomes containing long non-coding RNA POU3F3, Eur. Rev. Med. Pharmacol. Sci., 21, 959
  146. You, 2015, Matrix metalloproteinase 13-containing exosomes promote nasopharyngeal carcinoma metastasis, Cancer Sci., 106, 1669, 10.1111/cas.12818 · DOI
  147. Wang, 2016, Multiple myeloma exosomes establish a favourable bone marrow microenvironment with enhanced angiogenesis and immunosuppression, J. Pathol., 239, 162, 10.1002/path.4712 · DOI
  148. Giusti, 2016, From glioblastoma to endothelial cells through extracellular vesicles: Messages for angiogenesis, Tumor Biol., 37, 12743, 10.1007/s13277-016-5165-0 · DOI
  149. Chan, 2015, Proteomic analysis of exosomes from nasopharyngeal carcinoma cell identifies intercellular transfer of angiogenic proteins, Int. J. Cancer, 137, 1830, 10.1002/ijc.29562 · DOI
  150. Lu, 2017, Exosomal tetraspanins mediate cancer metastasis by altering host microenvironment, Oncotarget, 8, 62803, 10.18632/oncotarget.19119 · DOI
  151. Choi, 2011, Proteomic analysis of microvesicles derived from human colorectal cancer ascites, Proteomics, 11, 2745, 10.1002/pmic.201100022 · DOI
  152. Maji, 2016, Exosomal Annexin II Promotes Angiogenesis and Breast Cancer Metastasis, Mol. Cancer Res., 15, 93, 10.1158/1541-7786.MCR-16-0163 · DOI
  153. Lang, 2017, Glioma cells enhance angiogenesis and inhibit endothelial cell apoptosis through the release of exosomes that contain long non-coding RNA CCAT2, Oncol. Rep., 38, 785, 10.3892/or.2017.5742 · DOI
  154. Mao, 2019, Hypoxic exosomes facilitate angiogenesis and metastasis in esophageal squamous cell carcinoma through altering the phenotype and transcriptome of endothelial cells, J. Exp. Clin. Cancer Res., 38, 389, 10.1186/s13046-019-1384-8 · DOI
  155. Xie, 2019, The role of exosomal noncoding RNAs in cancer, Mol. Cancer, 18, 37, 10.1186/s12943-019-0984-4 · DOI
  156. Hsu, 2017, Hypoxic lung cancer-secreted exosomal miR-23a increased angiogenesis and vascular permeability by targeting prolyl hydroxylase and tight junction protein ZO-1, Oncogene, 36, 4929, 10.1038/onc.2017.105 · DOI
  157. Sruthi, 2017, Horizontal transfer of miR-23a from hypoxic tumor cell colonies can induce angiogenesis, J. Cell. Physiol., 233, 3498, 10.1002/jcp.26202 · DOI
  158. Deng, 2020, Exosome miR-155 Derived from Gastric Carcinoma Promotes Angiogenesis by Targeting the c-MYB/VEGF Axis of Endothelial Cells, Mol. Ther. Nucleic Acids, 19, 1449, 10.1016/j.omtn.2020.01.024 · DOI
  159. Duechler, 2014, MiRNA in melanoma-derived exosomes, Cancer Lett., 347, 29, 10.1016/j.canlet.2014.02.004 · DOI
  160. Wozniak, 2017, Analysis of the miRNA Profiles of Melanoma Exosomes Derived Under Normoxic and Hypoxic Culture Conditions, Anticancer Res., 37, 6779
  161. Yang, 2018, Exosome-Derived miR-130a Activates Angiogenesis in Gastric Cancer by Targeting C-MYB in Vascular Endothelial Cells, Mol. Ther., 26, 2466, 10.1016/j.ymthe.2018.07.023 · DOI
  162. Zhang, 2018, Exosomes serve as nanoparticles to suppress tumor growth and angiogenesis in gastric cancer by delivering hepatocyte growth factor siRNA, Cancer Sci., 109, 629, 10.1111/cas.13488 · DOI
  163. Allegra, 2011, Phase III Trial Assessing Bevacizumab in Stages II and III Carcinoma of the Colon: Results of NSABP Protocol C-08, J. Clin. Oncol., 29, 11, 10.1200/JCO.2010.30.0855 · DOI
  164. Schmoll, 2012, Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): A phase 3 randomised controlled trial, Lancet Oncol., 13, 1225, 10.1016/S1470-2045(12)70509-0 · DOI · Paper page
  165. Escudier, 2010, Phase III Trial of Bevacizumab Plus Interferon Alfa-2a in Patients with Metastatic Renal Cell Carcinoma (AVOREN): Final Analysis of Overall Survival, J. Clin. Oncol., 28, 2144, 10.1200/JCO.2009.26.7849 · DOI
  166. Montero, 2012, Bevacizumab in the treatment of metastatic breast cancer: Friend or foe?, Curr. Oncol. Rep., 14, 1, 10.1007/s11912-011-0202-z · DOI
  167. Qu, 2016, Exosome-Transmitted lncARSR Promotes Sunitinib Resistance in Renal Cancer by Acting as a Competing Endogenous RNA, Cancer Cell, 29, 653, 10.1016/j.ccell.2016.03.004 · DOI
  168. Gomi, 2007, Rab27b Is Expressed in a Wide Range of Exocytic Cells and Involved in the Delivery of Secretory Granules Near the Plasma Membrane, Mol. Biol. Cell, 18, 4377, 10.1091/mbc.e07-05-0409 · DOI
  169. Hendrix, 2010, Effect of the Secretory Small GTPase Rab27B on Breast Cancer Growth, Invasion, and Metastasis, J. Natl. Cancer Inst., 102, 866, 10.1093/jnci/djq153 · DOI
  170. Ostenfeld, 2014, Cellular Disposal of miR23b by RAB27-Dependent Exosome Release Is Linked to Acquisition of Metastatic Properties, Cancer Res., 74, 5758, 10.1158/0008-5472.CAN-13-3512 · DOI
  171. Wang, 2015, Hypomethylated Rab27b is a progression-associated prognostic biomarker of glioma regulating MMP-9 to promote invasion, Oncol. Rep., 34, 1503, 10.3892/or.2015.4125 · DOI
  172. Tsuruda, M., Yoshino, H., Okamura, S., Kuroshima, K., Osako, Y., Sakaguchi, T., Sugita, S., Tatarano, S., Nakagawa, M., and Enokida, H. (2020). Oncogenic effects of RAB27B through exosome independent function in renal cell carcinoma including sunitinib-resistant. PLoS ONE, 15. · DOI
  173. Maglione, 1991, Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor, Proc. Natl. Acad. Sci. USA, 88, 9267, 10.1073/pnas.88.20.9267 · DOI
  174. Park, 1994, Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR, J. Biol. Chem., 269, 25646, 10.1016/S0021-9258(18)47298-5 · DOI
  175. Cesi, 2018, A new ALK isoform transported by extracellular vesicles confers drug resistance to melanoma cells, Mol. Cancer, 17, 145, 10.1186/s12943-018-0886-x · DOI
  176. Yang, 2019, ZIP4 Promotes Muscle Wasting and Cachexia in Mice with Orthotopic Pancreatic Tumors by Stimulating RAB27B-Regulated Release of Extracellular Vesicles from Cancer Cells, Gastroenterology, 156, 722, 10.1053/j.gastro.2018.10.026 · DOI
  177. Simon, 2018, Shedding of bevacizumab in tumour cells-derived extracellular vesicles as a new therapeutic escape mechanism in glioblastoma, Mol. Cancer, 17, 132, 10.1186/s12943-018-0878-x · DOI
  178. Coimbra, 2016, Cetuximab treatment alters the content of extracellular vesicles released from tumor cells, Nanomedicine, 11, 881, 10.2217/nnm-2015-0009 · DOI
  179. Lorenc, T., Klimczyk, K., Michalczewska, I., Słomka, M., Kubiak-Tomaszewska, G., and Olejarz, W. (2020). Exosomes in Prostate Cancer Diagnosis, Prognosis and Therapy. Int. J. Mol. Sci., 21. · DOI
  180. Thery, 2002, Exosomes: Composition, biogenesis and function, Nat. Rev. Immunol., 2, 569, 10.1038/nri855 · DOI
  181. Yeo, 2013, Mesenchymal stem cell: An efficient mass producer of exosomes for drug delivery, Adv. Drug Deliv. Rev., 65, 336, 10.1016/j.addr.2012.07.001 · DOI · Paper page
  182. Mendt, 2019, Mesenchymal stem cell-derived exosomes for clinical use, Bone Marrow Transplant., 54, 789, 10.1038/s41409-019-0616-z · DOI
  183. Naseri, 2018, Exosome-mediated delivery of functionally active miRNA-142-3p inhibitor reduces tumorigenicity of breast cancer in vitro and in vivo, Int. J. Nanomed., 13, 7727, 10.2147/IJN.S182384 · DOI
  184. De La Torre, P., Pérez-Lorenzo, M.J., Alcázar-Garrido, Á., and Flores, A.I. (2020). Cell-Based Nanoparticles Delivery Systems for Targeted Cancer Therapy: Lessons from Anti-Angiogenesis Treatments. Molecules, 25. · DOI
  185. Jung, 2018, Development and MPI tracking of novel hypoxia-targeted theranostic exosomes, Biomaterials, 177, 139, 10.1016/j.biomaterials.2018.05.048 · DOI
  186. Kalluri, 2016, The biology and function of exosomes in cancer, J. Clin. Investig., 126, 1208, 10.1172/JCI81135 · DOI
  187. Lu, 2018, Exosomal miR-9 inhibits angiogenesis by targeting MDK and regulating PDK/AKT pathway in nasopharyngeal carcinoma, J. Exp. Clin. Cancer Res., 37, 147, 10.1186/s13046-018-0814-3 · DOI
  188. Bandari, 2017, Chemotherapy induces secretion of exosomes loaded with heparanase that degrades extracellular matrix and impacts tumor and host cell behavior, Matrix Biol., 65, 104, 10.1016/j.matbio.2017.09.001 · DOI
  189. Saari, 2015, Microvesicle- and exosome-mediated drug delivery enhances the cytotoxicity of Paclitaxel in autologous prostate cancer cells, J. Control. Release, 220, 727, 10.1016/j.jconrel.2015.09.031 · DOI · Paper page
  190. Islam, 2018, Augmentation of the Enhanced Permeability and Retention Effect with Nitric Oxide–Generating Agents Improves the Therapeutic Effects of Nanomedicines, Mol. Cancer Ther., 17, 2643, 10.1158/1535-7163.MCT-18-0696 · DOI
  191. Maeda, 2012, Macromolecular therapeutics in cancer treatment: The EPR effect and beyond, J. Control. Release, 164, 138, 10.1016/j.jconrel.2012.04.038 · DOI
  192. Fang, J., Islam, W., and Maeda, H. (2020). Exploiting the dynamics of the EPR effect and strategies to improve the therapeutic effects of nanomedicines by using EPR effect enhancers. Adv. Drug Deliv. Rev. · DOI · Paper page
  193. Maeda, 2018, Analyses of repeated failures in cancer therapy for solid tumors: Poor tumor-selective drug delivery, low therapeutic efficacy and unsustainable costs, Clin. Transl. Med., 7, 11, 10.1186/s40169-018-0185-6 · DOI · Paper page
  194. Katayama, Y., Uchino, J., Chihara, Y., Tamiya, N., Kaneko, Y., Yamada, T., and Takayama, K. (2019). Tumor Neovascularization and Developments in Therapeutics. Cancers, 11. · DOI
  195. Georganaki, 2018, Vascular Targeting to Increase the Efficiency of Immune Checkpoint Blockade in Cancer, Front. Immunol., 9, 3081, 10.3389/fimmu.2018.03081 · DOI

Cited by

Sorted by citations

See all 299

Metadata

Authors
Olejarz, W., Kubiak-Tomaszewska, G., Chrzanowska, A., & Lorenc, T.
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2020-08-14
Volume
21
Issue
16
Pages
5840
ISSN
1422-0067
DOI
10.3390/ijms21165840
PMC
PMC7461570
Cited by
299
References
17
Language
en
Licence
creativecommons.org/licenses/by/4.0/ (vor)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review